{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:07:04Z","timestamp":1784297224688,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001139","name":"ACT Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Paediatrics Child Health"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess changes in Respiratory Syncytial Virus (RSV) epidemiology and hospitalisations following implementation of a limited\u2010eligibility nirsevimab program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational cohort study included all infants aged &lt;\u20092\u2009years residing in our jurisdiction with laboratory\u2010confirmed RSV and\/or receipt of an RSV monoclonal antibody between April 2022 and March 2025. Cases were followed for emergency department (ED) presentations and hospital admissions. Primary outcomes were RSV incidence, ED presentation, and hospitalisation rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 2355 RSV cases, with 1625 infants presenting to ED and 701 hospitalised. Among 308 infants receiving nirsevimab, the most common indication was prematurity; 2.4% experienced breakthrough RSV infection. RSV incidence increased post\u2010nirsevimab (April 2024\u2013March 2025: 89.06\/1000 infant\u2010years) compared with the pre\u2010nirsevimab period (April 2022\u2013March 2024: 67.99\/1000 infant\u2010years), consistent with local and national trends. Characteristics of hospitalised infants changed in the post\u2010nirsevimab period: age increased (from 9.4 to 10.7\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019), the proportion aged &lt;\u20093\u2009months decreased (from 27.6% to 19.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013) and prematurity prevalence nearly halved (from 13.3% to 7.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). Clinical characteristics also changed, with an 8\u2010h reduction in length of stay (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010), and a one fifth reduction in the need for respiratory support (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). No significant differences were observed for Aboriginal and Torres Strait Islander infants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hospitalisations among infants at greatest risk for severe RSV disease reduced following introduction of the limited\u2010eligibility nirsevimab program. However, Aboriginal and Torres Strait Islander infants remained over\u2010represented in hospital admissions and under\u2010served by the program in its first year, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jpc.70402","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:34:29Z","timestamp":1778060069000},"page":"1168-1177","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Limited\u2010Eligibility Nirsevimab on Paediatric Respiratory Syncytial Virus (\n                    <scp>RSV<\/scp>\n                    ) Infection and Hospitalisations in the Australian Capital Territory: An Observational Cohort Study"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2334-073X","authenticated-orcid":false,"given":"Nicola","family":"Irwin","sequence":"first","affiliation":[{"name":"Department of Paediatrics Canberra Health Services  Canberra Australian Capital Territory Australia"},{"name":"Faculty of Health University of Canberra  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shevaun","family":"Ey","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Canberra Health Services  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology Australian National University  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Raina","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Canberra Health Services  Canberra Australian Capital Territory Australia"},{"name":"School of Medicine and Psychology Australian National University  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Richardson","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology Australian National University  Canberra Australian Capital Territory Australia"},{"name":"Department of Emergency Medicine The Canberra Hospital  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac216"},{"key":"e_1_2_12_4_1","unstructured":"Australian Centre for Disease Control \u201c2024 Annual Australian Respiratory Surveillance Report \u201dCanberra Australia (2024)."},{"key":"e_1_2_12_5_1","volume-title":"Protection Against RSV for Mums and Bubs With Free Vaccine Available From 3 February","author":"The Hon Mark Butler MP","year":"2025"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01716-1"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.70165"},{"key":"e_1_2_12_8_1","volume-title":"Australian Immunisation Handbook","author":"Australian Technical Advisory Group on Immunisation (ATAGI)","year":"2024"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52671"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(25)00102-6"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060640"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(25)00093-8"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581970"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106466"},{"issue":"2","key":"e_1_2_12_15_1","article-title":"Respiratory Syncytial Virus Epidemiology and Effectiveness of Infant Nirsevimab: 2024 Results From the Australian Sentinel Hospital Network (FluCAN\u2010PAEDS)","volume":"31","author":"Blyth C. C.","year":"2026","journal-title":"Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin"},{"key":"e_1_2_12_16_1","volume-title":"National, State and Territory Population","author":"Australian Bureau of Statistics","year":"2024"},{"key":"e_1_2_12_17_1","volume-title":"Mothers & Babies Dashboard Data. HealthStats ACT","author":"ACT Health and Community Services Directorate","year":"2025"},{"key":"e_1_2_12_18_1","volume-title":"Socio\u2010Economic Indexes for Areas (SEIFA), Australia","author":"Australian Bureau of Statistics","year":"2023"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.70144"},{"key":"e_1_2_12_20_1","volume-title":"ACT Respiratory Illness Surveillance Report 2024","author":"ACT Health","year":"2024"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-025-06125-5"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-024-05634-z"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29483"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101160"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.70066"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2025-328666"},{"key":"e_1_2_12_28_1","volume-title":"Estimates of Aboriginal and Torres Strait Islander Australians","author":"Australian Bureau of Statistics","year":"2021"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101654"},{"key":"e_1_2_12_30_1","volume-title":"Births, Australia","author":"Australian Bureau of Statistics","year":"2024"},{"key":"e_1_2_12_31_1","volume-title":"Annual Immunisation Coverage Report 2024 \u2013 Interim Data Release","author":"National Centre for Immunisation Research and Surveillance Australia","year":"2025"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anzjph.2024.100206"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.14175"},{"key":"e_1_2_12_34_1","unstructured":"National Centre for Immunisation Research and Surveillance Australia \u201cMaternal RSV Vaccine Uptake Data \u201dWestmead Australia 2025."}],"container-title":["Journal of Paediatrics and Child Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jpc.70402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jpc.70402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jpc.70402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:40:49Z","timestamp":1784295649000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jpc.70402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/jpc.70402"],"URL":"https:\/\/doi.org\/10.1111\/jpc.70402","archive":["Portico"],"relation":{},"ISSN":["1034-4810","1440-1754"],"issn-type":[{"value":"1034-4810","type":"print"},{"value":"1440-1754","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"2025-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}